Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity

Morag-Sela, Tamar; Cohn, Ilan; Kowalski, Thomas J.; Jarecki-Black, Judy; Clyde-Watson, Zoe
December 2004
Nature Biotechnology;Dec2004, Vol. 22 Issue 12, p1591
Academic Journal
The article discusses issues related to intellectual property (IP) rights to pharmaceuticals in Israel. The country has a very strong generic pharmaceutical industry. Israel's past record of defending and respecting IP rights has led major companies around the world to file patent applications in Israel, and seek Israeli patents. Because Israel seems to be further debating the issue of data exclusivity, with a view towards reaching some sort of accommodation with the U.S., the U.S. appears to applying less pressure.


Related Articles

  • A "Calibrated Approach": Pharmaceutical FDI and the Evolution of Indian Patent Law. Linton, Katherine Connor; Corrado, Nicholas // Journal of International Commerce & Economics;Aug2008, Vol. I, p163 

    India has charted its own intellectual property (IP) path over the last 35 years, attempting to foster the growth of a domestic pharmaceutical industry and access to medicine while, more recently, also addressing the requirements of the international IP regime. Multinational companies (MNCs)...

  • India: Multi-national pharmaceutical company challenges patent law. Betteridge, Glenn // HIV/AIDS Policy & Law Review;May2007, Vol. 12 Issue 1, p35 

    The article reports on the outcome of the implementation of India's Patents Act which was amended to bring India into compliance with its obligations under the World Trade Organization's (WHO) Agreement on Trade-Related Aspects of Intellectual Property Rights. The section was made to avoid...

  • The High Price of 'Free' Trade: U.S. Trade Agreements and Access to Medicines. Lopert, Ruth; Gleeson, Deborah // Journal of Law, Medicine & Ethics;Spring2013, Vol. 41 Issue 1, p199 

    The United States' pursuit of increasingly TRIPS-Plus levels of intellectual property protection for medicines in bilateral and regional trade agreements is well recognized. Less so, however, are U.S. efforts through these agreements to influence and constrain the pharmaceutical coverage...

  • Intellectual property, pharmaceutical MNEs and the developing world. Ghauri, Pervez N.; Rao, P.M. // Journal of World Business;Apr2009, Vol. 44 Issue 2, p206 

    Abstract: The paper examines the structure of pharmaceutical R&D funding, spillovers and public�private-academic research linkages in the developing countries. The paper also examines several policy options aimed at mitigating the trade off between the twin and often conflicting objectives...

  • Caution needed for Russian Expansion.  // Pharmaceutical Technology Europe;Jul2006, Vol. 18 Issue 7, p10 

    The article indicates that accounting and consulting firm PricewaterhouseCoopers has released a report on the opportunities and problems associated with the pharmaceutical industry in Russia. It was observed that the legal system is much weaker than in the European Union, U.S. or Japan, and that...

  • The production of generic drugs in India: Would be affected by new trade agreement with EU. Love, James // BMJ: British Medical Journal (International Edition);4/2/2011, Vol. 342 Issue 7800, p721 

    The author reflects on the trade agreement negotiated between European Union (EU) and India which may affect the production of generic drugs. The author says that the deal, which restricts ownership and enforcement of intellectual property for medical inventions, if implemented, may shrink the...

  • Thomson Reuters: 'One World, One Source' BRYNKO, BARBARA // Information Today;Jul/Aug2012, Vol. 29 Issue 7, p31 

    The article evaluates the Saegis on Serion platform solution trademark content database by Thomson CompuMark, a business of Thomson Reuters Intellectual Property and Science.

  • Thomson Reuters: One-Stop IP Management.  // Information Today;May2013, Vol. 30 Issue 5, p13 

    The article profiles the international business enterprise Thomson Reuters and discusses several products and services which are available from the company, including the Derwent World Patents Index, the Thomson IP Manager and IP Payments from Thomson Reuters. A business relationship which was...

  • Whose Property Is It, Anyway?  // European Pharmaceutical Executive;May/Jun2006, p18 

    The article discusses the need for the pharmaceutical industry to change its attitude towards intellectual property to survive the changing climate of patent rights in Europe. It focuses on the issue of whether the possession of a single patent was sufficient grounds to bring someone else's...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics